Page last updated: 2024-08-26

lopinavir and amg531

lopinavir has been researched along with amg531 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D1
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
McLean, HB; Park, JW; Pendry, C; Peng, B; Theodore, D; Wire, MB1

Reviews

1 review(s) available for lopinavir and amg531

ArticleYear
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Trials

1 trial(s) available for lopinavir and amg531

ArticleYear
Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Benzoates; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Hydrazines; Lopinavir; Male; Middle Aged; Pyrazoles; Ritonavir; Young Adult

2012

Other Studies

2 other study(ies) available for lopinavir and amg531

ArticleYear
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells

2020
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

    Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors

2021
chemdatabank.com